Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Testare l'aggiunta di un farmaco antiangiogenico (bevacizumab) alla chemioterapia (carboplatina e paclitaxel) combinato con immunoterapia (pembrolizumab) per PMMR, carcinoma endometriale mutata TP53

18 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio randomizzato di fase II/III di carboplatina, paclitaxel, pembrolizumab contro carboplatina, paclitaxel, bevacizumab contro carboplatina, paclitaxel, pembrolizumab, bevacizumab nel trattamento di pmmr, tp53 mutated ourometriale endometriale endometriale endometriale recupera

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To demonstrate that bevacizumab, an anti-VEGF antibody therapy, (or an anti-VEGF antibody biosimilar) in combination with carboplatin, paclitaxel, and pembrolizumab is superior to carboplatin, paclitaxel, and pembrolizumab (the control arm) or carboplatin, paclitaxel, and bevacizumab in prolonging progression-free survival (PFS) in patients with pMMR, TP53 mutated advanced stage (III or IV) or recurrent endometrial cancer.

SECONDARY OBJECTIVES:

I. To demonstrate that bevacizumab in combination with carboplatin, paclitaxel, and pembrolizumab is superior to carboplatin, paclitaxel, and pembrolizumab or carboplatin, paclitaxel, and bevacizumab in prolonging overall survival (OS) in patients with pMMR, TP53 mutated advanced stage (III or IV) or recurrent endometrial cancer.

II. To examine the impact of the addition of bevacizumab in combination with carboplatin and paclitaxel or with carboplatin, paclitaxel, and pembrolizumab on PFS and OS based on type of p53 immunohistochemistry (IHC) aberrancy (over expression/cytoplasmic expression versus null [complete absence of staining]) and mutation type.

III. To evaluate toxicity on treatment with bevacizumab when combined with carboplatin, paclitaxel, and/or pembrolizumab as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.)5.0.

IV. To explore the anti-tumor activity in each treatment arm as assessed by objective response rate in the subset of patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM 1 (REFERENCE ARM): Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to an additional14 cycles. Additionally, patients undergo urine and blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.

ARM 2 (EXPERIMENTAL TRIPLET ARM): Patients receive paclitaxel IV over 3 hours, carboplatin IV, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

ARM 3 (EXPERIMENTAL QUADRUPLET ARM): Patients receive paclitaxel IV over 3 hours, carboplatin IV, pembrolizumab IV over 30 minutes, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes every 6 weeks for up to an additional 14 cycles and bevacizumab IV every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

After completion of study treatment, patients are followed every 3 months for 2 years then every 6 months for up to 3 years.

Tipo di studio

Interventistico

Iscrizione (Stimato)

255

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Reclutamento
        • University of Alabama at Birmingham Cancer Center
        • Investigatore principale:
          • Michael D. Toboni
        • Contatto:
    • Alaska
      • Anchorage, Alaska, Stati Uniti, 99508
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85004
      • Tucson, Arizona, Stati Uniti, 85719
        • Reclutamento
        • Banner University Medical Center - Tucson
        • Contatto:
        • Investigatore principale:
          • Marina D. Miller
      • Tucson, Arizona, Stati Uniti, 85719
        • Reclutamento
        • University of Arizona Cancer Center-North Campus
        • Contatto:
        • Investigatore principale:
          • Marina D. Miller
    • Arkansas
      • Fayetteville, Arkansas, Stati Uniti, 72703
        • Reclutamento
        • Highlands Oncology Group - Fayetteville
        • Investigatore principale:
          • Joseph T. Beck
        • Contatto:
      • Little Rock, Arkansas, Stati Uniti, 72205
        • Reclutamento
        • University of Arkansas for Medical Sciences
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 501-686-8274
        • Investigatore principale:
          • Heather R. Williams
      • Rogers, Arkansas, Stati Uniti, 72758
        • Reclutamento
        • Highlands Oncology Group - Rogers
        • Investigatore principale:
          • Joseph T. Beck
        • Contatto:
      • Springdale, Arkansas, Stati Uniti, 72762
        • Reclutamento
        • Highlands Oncology Group
        • Investigatore principale:
          • Joseph T. Beck
        • Contatto:
    • California
      • Carmichael, California, Stati Uniti, 95608
      • Carmichael, California, Stati Uniti, 95608
      • Dublin, California, Stati Uniti, 94568
        • Reclutamento
        • Kaiser Permanente Dublin
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
      • Elk Grove, California, Stati Uniti, 95758
      • Fremont, California, Stati Uniti, 94538
        • Reclutamento
        • Kaiser Permanente-Fremont
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Fresno, California, Stati Uniti, 93720
        • Reclutamento
        • Kaiser Permanente Fresno Orchard Plaza
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 833-574-2273
      • Los Angeles, California, Stati Uniti, 90048
        • Reclutamento
        • Cedars-Sinai Medical Center
        • Investigatore principale:
          • Emily N. Prendergast
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • USC / Norris Comprehensive Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 323-865-0451
        • Investigatore principale:
          • Koji Matsuo
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • Los Angeles General Medical Center
        • Investigatore principale:
          • Koji Matsuo
        • Contatto:
      • Modesto, California, Stati Uniti, 95356
        • Reclutamento
        • Kaiser Permanente- Modesto MOB II
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
      • Oakland, California, Stati Uniti, 94611
        • Reclutamento
        • Kaiser Permanente-Oakland
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Palo Alto, California, Stati Uniti, 94304
        • Reclutamento
        • Stanford Cancer Institute Palo Alto
        • Investigatore principale:
          • Kristin L. Bixel
        • Contatto:
      • Rancho Mirage, California, Stati Uniti, 92270
        • Reclutamento
        • Eisenhower Medical Center
        • Investigatore principale:
          • Mark Genesen
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 760-834-3798
      • Rocklin, California, Stati Uniti, 95765
      • Roseville, California, Stati Uniti, 95661
        • Reclutamento
        • Kaiser Permanente-Roseville
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Sacramento, California, Stati Uniti, 95817
        • Reclutamento
        • University of California Davis Comprehensive Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 916-734-3089
        • Investigatore principale:
          • Nancy T. Nguyen
      • Sacramento, California, Stati Uniti, 95814
        • Reclutamento
        • Kaiser Permanente Downtown Commons
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: kpoct@kp.org
      • Sacramento, California, Stati Uniti, 95823
        • Reclutamento
        • Kaiser Permanente-South Sacramento
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Sacramento, California, Stati Uniti, 95816
      • San Francisco, California, Stati Uniti, 94115
        • Reclutamento
        • Kaiser Permanente-San Francisco
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • San Jose, California, Stati Uniti, 95119
        • Reclutamento
        • Kaiser Permanente-Santa Teresa-San Jose
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • San Leandro, California, Stati Uniti, 94577
        • Reclutamento
        • Kaiser Permanente San Leandro
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • San Rafael, California, Stati Uniti, 94903
        • Reclutamento
        • Kaiser San Rafael-Gallinas
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Santa Clara, California, Stati Uniti, 95051
        • Reclutamento
        • Kaiser Permanente Medical Center - Santa Clara
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Santa Rosa, California, Stati Uniti, 95403
        • Reclutamento
        • Kaiser Permanente-Santa Rosa
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • South San Francisco, California, Stati Uniti, 94080
        • Reclutamento
        • Kaiser Permanente-South San Francisco
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Vallejo, California, Stati Uniti, 94589
        • Reclutamento
        • Kaiser Permanente-Vallejo
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Walnut Creek, California, Stati Uniti, 94596
        • Reclutamento
        • Kaiser Permanente-Walnut Creek
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
      • Woodland, California, Stati Uniti, 95695
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • UCHealth University of Colorado Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 720-848-0650
        • Investigatore principale:
          • Bradley R. Corr
      • Colorado Springs, Colorado, Stati Uniti, 80909
        • Reclutamento
        • UCHealth Memorial Hospital Central
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 719-365-2406
        • Investigatore principale:
          • Bradley R. Corr
      • Colorado Springs, Colorado, Stati Uniti, 80920
        • Reclutamento
        • Memorial Hospital North
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 719-364-6700
        • Investigatore principale:
          • Bradley R. Corr
      • Fort Collins, Colorado, Stati Uniti, 80524
        • Reclutamento
        • Poudre Valley Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 970-297-6150
        • Investigatore principale:
          • Bradley R. Corr
      • Fort Collins, Colorado, Stati Uniti, 80528
        • Reclutamento
        • Cancer Care and Hematology-Fort Collins
        • Contatto:
        • Investigatore principale:
          • Bradley R. Corr
      • Greeley, Colorado, Stati Uniti, 80631
        • Reclutamento
        • UCHealth Greeley Hospital
        • Contatto:
        • Investigatore principale:
          • Bradley R. Corr
      • Highlands Ranch, Colorado, Stati Uniti, 80129
        • Reclutamento
        • UCHealth Highlands Ranch Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 720-848-0650
        • Investigatore principale:
          • Bradley R. Corr
      • Loveland, Colorado, Stati Uniti, 80538
        • Reclutamento
        • Medical Center of the Rockies
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 970-203-7083
        • Investigatore principale:
          • Bradley R. Corr
    • Connecticut
      • Hartford, Connecticut, Stati Uniti, 06102
        • Reclutamento
        • Hartford Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 860-545-5363
        • Investigatore principale:
          • Amy K. Brown
      • Manchester, Connecticut, Stati Uniti, 06042
        • Reclutamento
        • Hartford HealthCare - Manchester
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 860-972-4700
        • Investigatore principale:
          • Amy K. Brown
      • New Britain, Connecticut, Stati Uniti, 06050
        • Reclutamento
        • The Hospital of Central Connecticut
        • Investigatore principale:
          • Amy K. Brown
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 860-224-5660
    • Delaware
      • Millville, Delaware, Stati Uniti, 19967
        • Reclutamento
        • Beebe South Coastal Health Campus
        • Contatto:
        • Investigatore principale:
          • Gregory A. Masters
      • Newark, Delaware, Stati Uniti, 19713
        • Reclutamento
        • Helen F Graham Cancer Center
        • Investigatore principale:
          • Gregory A. Masters
        • Contatto:
      • Newark, Delaware, Stati Uniti, 19713
        • Reclutamento
        • Medical Oncology Hematology Consultants PA
        • Investigatore principale:
          • Gregory A. Masters
        • Contatto:
      • Rehoboth Beach, Delaware, Stati Uniti, 19971
        • Reclutamento
        • Beebe Health Campus
        • Contatto:
        • Investigatore principale:
          • Gregory A. Masters
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Reclutamento
        • MedStar Washington Hospital Center
        • Investigatore principale:
          • Ebony R. Hoskins
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 202-877-8839
    • Florida
      • N. Venice, Florida, Stati Uniti, 34275
        • Reclutamento
        • Sarasota Memorial Hospital-Venice
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 941-261-9000
        • Investigatore principale:
          • Toni P. Kilts
      • Sarasota, Florida, Stati Uniti, 34239
        • Reclutamento
        • Sarasota Memorial Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 941-917-2225
        • Investigatore principale:
          • Toni P. Kilts
      • Sarasota, Florida, Stati Uniti, 34243
        • Reclutamento
        • Sarasota Memorial Health Care Center at University Parkway
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 941-917-6519
        • Investigatore principale:
          • Toni P. Kilts
      • Sarasota, Florida, Stati Uniti, 34239
        • Reclutamento
        • Florida Cancer Specialists - Sarasota Downtown
        • Contatto:
        • Investigatore principale:
          • Toni P. Kilts
      • Sarasota, Florida, Stati Uniti, 34239
        • Reclutamento
        • FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery
        • Contatto:
        • Investigatore principale:
          • Toni P. Kilts
      • Venice, Florida, Stati Uniti, 34275
        • Reclutamento
        • Florida Cancer Specialists - Venice Pinebrook
        • Contatto:
        • Investigatore principale:
          • Toni P. Kilts
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University Hospital/Winship Cancer Institute
        • Investigatore principale:
          • Kristen Starbuck
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 404-778-1868
      • Atlanta, Georgia, Stati Uniti, 30303
        • Reclutamento
        • Grady Health System
        • Investigatore principale:
          • Kristen Starbuck
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 404-778-1868
      • Atlanta, Georgia, Stati Uniti, 30308
        • Reclutamento
        • Emory University Hospital Midtown
        • Investigatore principale:
          • Kristen Starbuck
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 888-946-7447
      • Augusta, Georgia, Stati Uniti, 30912
        • Reclutamento
        • Augusta University Medical Center
        • Contatto:
        • Investigatore principale:
          • Bunja J. Rungruang
      • Decatur, Georgia, Stati Uniti, 30033
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96826
        • Reclutamento
        • Kapiolani Medical Center for Women and Children
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 808-983-6090
        • Investigatore principale:
          • Michael E. Carney
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Reclutamento
        • Hawaii Cancer Care Inc - Waterfront Plaza
        • Contatto:
        • Investigatore principale:
          • Michael E. Carney
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Reclutamento
        • Queen's Cancer Cenrer - POB I
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 808-532-0315
        • Investigatore principale:
          • Michael E. Carney
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Reclutamento
        • Queen's Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 808-545-8548
        • Investigatore principale:
          • Michael E. Carney
      • Honolulu, Hawaii, Stati Uniti, 96817
        • Reclutamento
        • Queen's Cancer Center - Kuakini
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 808-531-8521
        • Investigatore principale:
          • Michael E. Carney
      • Honolulu, Hawaii, Stati Uniti, 96819
        • Reclutamento
        • Kaiser Permanente Moanalua Medical Center
        • Investigatore principale:
          • Juraj Kavecansky
        • Contatto:
      • ‘Aiea, Hawaii, Stati Uniti, 96701
        • Reclutamento
        • Pali Momi Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 808-486-6000
        • Investigatore principale:
          • Michael E. Carney
      • ‘Aiea, Hawaii, Stati Uniti, 96701
        • Reclutamento
        • Queen's Cancer Center - Pearlridge
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 808-487-7447
        • Investigatore principale:
          • Michael E. Carney
      • ‘Ewa Beach, Hawaii, Stati Uniti, 96706
        • Reclutamento
        • The Queen's Medical Center - West Oahu
        • Contatto:
        • Investigatore principale:
          • Michael E. Carney
    • Idaho
      • Coeur d'Alene, Idaho, Stati Uniti, 83814
        • Reclutamento
        • Kootenai Health - Coeur d'Alene
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Post Falls, Idaho, Stati Uniti, 83854
        • Reclutamento
        • Kootenai Clinic Cancer Services - Post Falls
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Sandpoint, Idaho, Stati Uniti, 83864
        • Reclutamento
        • Kootenai Clinic Cancer Services - Sandpoint
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Alyssa Bujnak
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern University
        • Contatto:
        • Investigatore principale:
          • Emma Barber
      • Chicago, Illinois, Stati Uniti, 60612
        • Reclutamento
        • Rush MD Anderson Cancer Center
        • Investigatore principale:
          • Alexander C. Cohen
        • Contatto:
      • Danville, Illinois, Stati Uniti, 61832
        • Reclutamento
        • Carle at The Riverfront
        • Investigatore principale:
          • Pratima Chalasani
        • Contatto:
      • DeKalb, Illinois, Stati Uniti, 60115
        • Reclutamento
        • Northwestern Medicine Cancer Center Kishwaukee
        • Contatto:
        • Investigatore principale:
          • Emma Barber
      • Decatur, Illinois, Stati Uniti, 62526
        • Reclutamento
        • Cancer Care Specialists of Illinois - Decatur
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Decatur, Illinois, Stati Uniti, 62526
        • Reclutamento
        • Decatur Memorial Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Effingham, Illinois, Stati Uniti, 62401
        • Reclutamento
        • Carle Physician Group-Effingham
        • Contatto:
        • Investigatore principale:
          • Pratima Chalasani
      • Evanston, Illinois, Stati Uniti, 60201
        • Reclutamento
        • NorthShore University HealthSystem-Evanston Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-570-2109
        • Investigatore principale:
          • Mary T. Jenkins Vogel
      • Geneva, Illinois, Stati Uniti, 60134
        • Reclutamento
        • Northwestern Medicine Cancer Center Delnor
        • Contatto:
        • Investigatore principale:
          • Emma Barber
      • Glenview, Illinois, Stati Uniti, 60026
        • Reclutamento
        • NorthShore University HealthSystem-Glenbrook Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-570-2109
        • Investigatore principale:
          • Mary T. Jenkins Vogel
      • Harvey, Illinois, Stati Uniti, 60426
        • Reclutamento
        • Ingalls Memorial Hospital
        • Contatto:
        • Investigatore principale:
          • Ivy Abraham
      • Highland Park, Illinois, Stati Uniti, 60035
        • Reclutamento
        • NorthShore University HealthSystem-Highland Park Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-570-2109
        • Investigatore principale:
          • Mary T. Jenkins Vogel
      • Mattoon, Illinois, Stati Uniti, 61938
        • Reclutamento
        • Carle Physician Group-Mattoon/Charleston
        • Contatto:
        • Investigatore principale:
          • Pratima Chalasani
      • New Lenox, Illinois, Stati Uniti, 60451
        • Reclutamento
        • UC Comprehensive Cancer Center at Silver Cross
        • Contatto:
        • Investigatore principale:
          • Alyssa Bujnak
      • Normal, Illinois, Stati Uniti, 61761
        • Reclutamento
        • Carle BroMenn Medical Center
        • Investigatore principale:
          • Pratima Chalasani
        • Contatto:
      • Normal, Illinois, Stati Uniti, 61761
        • Reclutamento
        • Carle Cancer Institute Normal
        • Investigatore principale:
          • Pratima Chalasani
        • Contatto:
      • O'Fallon, Illinois, Stati Uniti, 62269
        • Reclutamento
        • Cancer Care Center of O'Fallon
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • O'Fallon, Illinois, Stati Uniti, 62269
        • Reclutamento
        • HSHS Saint Elizabeth's Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Oak Brook, Illinois, Stati Uniti, 60523
      • Oak Park, Illinois, Stati Uniti, 60304
        • Reclutamento
        • Rush MD Anderson Cancer Center at Rush Oak Park
        • Investigatore principale:
          • Alexander C. Cohen
        • Contatto:
      • Orland Park, Illinois, Stati Uniti, 60462
        • Reclutamento
        • University of Chicago Medicine-Orland Park
        • Contatto:
        • Investigatore principale:
          • Alyssa Bujnak
      • Orland Park, Illinois, Stati Uniti, 60462
      • Peoria, Illinois, Stati Uniti, 61637
        • Reclutamento
        • OSF Saint Francis Medical Center
        • Contatto:
        • Investigatore principale:
          • Bryan A. Faller
      • Springfield, Illinois, Stati Uniti, 62702
        • Reclutamento
        • Southern Illinois University School of Medicine
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 217-545-7929
      • Springfield, Illinois, Stati Uniti, 62702
        • Reclutamento
        • Springfield Clinic
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-444-7541
      • Springfield, Illinois, Stati Uniti, 62781
        • Reclutamento
        • Springfield Memorial Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Urbana, Illinois, Stati Uniti, 61801
        • Reclutamento
        • Carle Cancer Center
        • Contatto:
        • Investigatore principale:
          • Pratima Chalasani
      • Warrenville, Illinois, Stati Uniti, 60555
        • Reclutamento
        • Northwestern Medicine Cancer Center Warrenville
        • Contatto:
        • Investigatore principale:
          • Emma Barber
    • Indiana
      • Crown Point, Indiana, Stati Uniti, 46307
        • Reclutamento
        • UChicago Medicine Northwest Indiana
        • Contatto:
        • Investigatore principale:
          • Alyssa Bujnak
      • Goshen, Indiana, Stati Uniti, 46526
        • Reclutamento
        • Goshen Center for Cancer Care
        • Contatto:
        • Investigatore principale:
          • Pamela J. Stone
      • Indianapolis, Indiana, Stati Uniti, 46260
        • Reclutamento
        • Ascension Saint Vincent Indianapolis Hospital
        • Contatto:
        • Investigatore principale:
          • Megan E. Buechel
      • South Bend, Indiana, Stati Uniti, 46601
        • Sospeso
        • Memorial Hospital of South Bend
    • Iowa
      • Ankeny, Iowa, Stati Uniti, 50023
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Carroll, Iowa, Stati Uniti, 51401
        • Reclutamento
        • Saint Anthony Regional Hospital
        • Contatto:
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Cedar Rapids, Iowa, Stati Uniti, 52403
        • Reclutamento
        • Mercy Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 319-365-4673
        • Investigatore principale:
          • Deborah W. Wilbur
      • Cedar Rapids, Iowa, Stati Uniti, 52403
        • Reclutamento
        • Oncology Associates at Mercy Medical Center
        • Investigatore principale:
          • Deborah W. Wilbur
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 319-363-2690
      • Clive, Iowa, Stati Uniti, 50325
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Stati Uniti, 50314
        • Reclutamento
        • Broadlawns Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-282-2200
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Stati Uniti, 50314
        • Reclutamento
        • Mercy Medical Center - Des Moines
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Richard L. Deming
      • Des Moines, Iowa, Stati Uniti, 50309
        • Reclutamento
        • Iowa Methodist Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-6727
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Stati Uniti, 50309
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Stati Uniti, 50314
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, Stati Uniti, 50501
        • Reclutamento
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
        • Investigatore principale:
          • Seema Harichand-Herdt
        • Contatto:
      • Iowa City, Iowa, Stati Uniti, 52242
        • Reclutamento
        • University of Iowa/Holden Comprehensive Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-237-1225
        • Investigatore principale:
          • David P. Bender
      • Waukee, Iowa, Stati Uniti, 50263
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • Reclutamento
        • University of Kentucky/Markey Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 859-257-3379
        • Investigatore principale:
          • Rachel W. Miller
      • Lexington, Kentucky, Stati Uniti, 40503
        • Reclutamento
        • Baptist Health Lexington
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 859-260-6425
        • Investigatore principale:
          • Hope Cottrill
    • Louisiana
      • Marrero, Louisiana, Stati Uniti, 70072
        • Reclutamento
        • West Jefferson Medical Center
        • Contatto:
        • Investigatore principale:
          • Tara Castellano
      • Metairie, Louisiana, Stati Uniti, 70006
        • Reclutamento
        • East Jefferson General Hospital
        • Contatto:
        • Investigatore principale:
          • Tara Castellano
      • Metairie, Louisiana, Stati Uniti, 70006
        • Reclutamento
        • LSU Healthcare Network / Metairie Multi-Specialty Clinic
        • Contatto:
        • Investigatore principale:
          • Tara Castellano
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Reclutamento
        • University Medical Center New Orleans
        • Contatto:
        • Investigatore principale:
          • Tara Castellano
    • Maine
      • Brewer, Maine, Stati Uniti, 04412
        • Reclutamento
        • Lafayette Family Cancer Center-EMMC
        • Investigatore principale:
          • Sarah J. Sinclair
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-987-3005
      • Scarborough, Maine, Stati Uniti, 04074
        • Reclutamento
        • MaineHealth Maine Medical Center- Scarborough
        • Investigatore principale:
          • Leslie S. Bradford
        • Contatto:
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Reclutamento
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Contatto:
        • Investigatore principale:
          • Amanda N. Fader
      • Baltimore, Maryland, Stati Uniti, 21237
        • Reclutamento
        • MedStar Franklin Square Medical Center/Weinberg Cancer Institute
        • Investigatore principale:
          • Ebony R. Hoskins
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 443-777-7364
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana-Farber Cancer Institute
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-442-3324
        • Investigatore principale:
          • Susana M. Campos
      • Burlington, Massachusetts, Stati Uniti, 01805
      • Peabody, Massachusetts, Stati Uniti, 01960
        • Reclutamento
        • Lahey Clinic Peabody
        • Contatto:
        • Investigatore principale:
          • Corrine L. Zarwan
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan Rogel Cancer Center
        • Contatto:
        • Investigatore principale:
          • Zhen Ni Zhou
      • Battle Creek, Michigan, Stati Uniti, 49017
        • Reclutamento
        • Bronson Battle Creek
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Brighton, Michigan, Stati Uniti, 48114
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Brighton, Michigan, Stati Uniti, 48116
        • Reclutamento
        • University of Michigan - Brighton Center for Specialty Care
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-865-1125
        • Investigatore principale:
          • Zhen Ni Zhou
      • Canton, Michigan, Stati Uniti, 48188
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Chelsea, Michigan, Stati Uniti, 48118
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Detroit, Michigan, Stati Uniti, 48201
        • Reclutamento
        • Wayne State University/Karmanos Cancer Institute
        • Investigatore principale:
          • Radhika P. Gogoi
        • Contatto:
      • Escanaba, Michigan, Stati Uniti, 49829
        • Reclutamento
        • OSF Saint Francis Hospital and Medical Group
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • Farmington Hills, Michigan, Stati Uniti, 48334
        • Reclutamento
        • Weisberg Cancer Treatment Center
        • Contatto:
        • Investigatore principale:
          • Radhika P. Gogoi
      • Flint, Michigan, Stati Uniti, 48503
        • Reclutamento
        • Genesys Hurley Cancer Institute
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Flint, Michigan, Stati Uniti, 48503
        • Reclutamento
        • Hurley Medical Center
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Flint, Michigan, Stati Uniti, 48503
        • Reclutamento
        • Cancer Hematology Centers - Flint
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Trinity Health Grand Rapids Hospital
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Stati Uniti, 49007
        • Reclutamento
        • Bronson Methodist Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Stati Uniti, 49007
        • Reclutamento
        • West Michigan Cancer Center
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Stati Uniti, 49009
        • Reclutamento
        • Beacon Kalamazoo Cancer Center
        • Investigatore principale:
          • Kathleen Y. Butler
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 574-647-7370
      • Lansing, Michigan, Stati Uniti, 48912
        • Reclutamento
        • University of Michigan Health - Sparrow Lansing
        • Investigatore principale:
          • J. R. Liu
        • Contatto:
      • Livonia, Michigan, Stati Uniti, 48154
        • Reclutamento
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Manistique, Michigan, Stati Uniti, 49854
        • Reclutamento
        • Schoolcraft Memorial Hospital
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • Muskegon, Michigan, Stati Uniti, 49444
        • Reclutamento
        • Trinity Health Muskegon Hospital
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Niles, Michigan, Stati Uniti, 49120
        • Reclutamento
        • Corewell Health Lakeland Hospitals - Niles Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 616-391-1230
        • Investigatore principale:
          • Kathleen Y. Butler
      • Norton Shores, Michigan, Stati Uniti, 49444
        • Reclutamento
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Pontiac, Michigan, Stati Uniti, 48341
        • Reclutamento
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
      • Reed City, Michigan, Stati Uniti, 49677
        • Reclutamento
        • Corewell Health Reed City Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Reclutamento
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Reclutamento
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Traverse City, Michigan, Stati Uniti, 49684
        • Reclutamento
        • Munson Medical Center
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Wyoming, Michigan, Stati Uniti, 49519
        • Reclutamento
        • University of Michigan Health - West
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Ypsilanti, Michigan, Stati Uniti, 48197
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contatto:
        • Investigatore principale:
          • J. R. Liu
    • Minnesota
      • Brainerd, Minnesota, Stati Uniti, 56401
        • Reclutamento
        • Essentia Health Saint Joseph's Medical Center
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Coon Rapids, Minnesota, Stati Uniti, 55433
        • Reclutamento
        • Mercy Hospital
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
      • Deer River, Minnesota, Stati Uniti, 56636
        • Reclutamento
        • Essentia Health - Deer River Clinic
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Duluth, Minnesota, Stati Uniti, 55805
        • Reclutamento
        • Essentia Health Cancer Center
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Edina, Minnesota, Stati Uniti, 55435
        • Reclutamento
        • Fairview Southdale Hospital
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
      • Edina, Minnesota, Stati Uniti, 55435
        • Reclutamento
        • Minnesota Oncology - Edina
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
      • Hibbing, Minnesota, Stati Uniti, 55746
        • Reclutamento
        • Essentia Health Hibbing Clinic
        • Investigatore principale:
          • Bret E. Friday
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 218-786-3308
      • Minneapolis, Minnesota, Stati Uniti, 55407
        • Reclutamento
        • Abbott-Northwestern Hospital
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • Reclutamento
        • University of Minnesota/Masonic Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 612-624-2620
        • Investigatore principale:
          • Alexandra Schefter
      • Saint Louis Park, Minnesota, Stati Uniti, 55416
        • Reclutamento
        • Park Nicollet Clinic - Saint Louis Park
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
      • Saint Paul, Minnesota, Stati Uniti, 55101
        • Reclutamento
        • Regions Hospital
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
      • Saint Paul, Minnesota, Stati Uniti, 55102
        • Reclutamento
        • United Hospital
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
      • Sandstone, Minnesota, Stati Uniti, 55072
        • Reclutamento
        • Essentia Health Sandstone
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Virginia, Minnesota, Stati Uniti, 55792
        • Reclutamento
        • Essentia Health Virginia Clinic
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Woodbury, Minnesota, Stati Uniti, 55125
        • Reclutamento
        • Minnesota Oncology Hematology PA-Woodbury
        • Investigatore principale:
          • Joleen M. Hubbard
        • Contatto:
    • Missouri
      • Columbia, Missouri, Stati Uniti, 65212
        • Reclutamento
        • MU Health - University Hospital/Ellis Fischel Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 573-882-7440
        • Investigatore principale:
          • Erin R. Tuller
      • Springfield, Missouri, Stati Uniti, 65804
        • Reclutamento
        • Mercy Hospital Springfield
        • Investigatore principale:
          • Jay W. Carlson
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 417-269-4520
      • Springfield, Missouri, Stati Uniti, 65807
        • Reclutamento
        • CoxHealth South Hospital
        • Investigatore principale:
          • Jay W. Carlson
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 417-269-4520
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine
        • Contatto:
        • Investigatore principale:
          • David G. Mutch
    • Montana
      • Anaconda, Montana, Stati Uniti, 59711
        • Reclutamento
        • Community Hospital of Anaconda
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Billings, Montana, Stati Uniti, 59101
        • Reclutamento
        • Billings Clinic Cancer Center
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Billings, Montana, Stati Uniti, 59102
        • Reclutamento
        • Saint Vincent Frontier Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-648-6274
        • Investigatore principale:
          • Megan Petersen
      • Billings, Montana, Stati Uniti, 59106
        • Reclutamento
        • Intermountain Health West End Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 406-238-6685
        • Investigatore principale:
          • Megan Petersen
      • Bozeman, Montana, Stati Uniti, 59715
        • Reclutamento
        • Bozeman Health Deaconess Hospital
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Great Falls, Montana, Stati Uniti, 59405
        • Reclutamento
        • Benefis Sletten Cancer Institute
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Kalispell, Montana, Stati Uniti, 59901
        • Reclutamento
        • Logan Health Medical Center
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Missoula, Montana, Stati Uniti, 59804
        • Reclutamento
        • Community Medical Center
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
    • Nebraska
      • Bellevue, Nebraska, Stati Uniti, 68123
        • Reclutamento
        • Nebraska Medicine-Bellevue
        • Contatto:
        • Investigatore principale:
          • Lindsey A. McAlarnen
      • Kearney, Nebraska, Stati Uniti, 68845
        • Reclutamento
        • Fred and Pamela Buffett Cancer Center - Kearney
        • Contatto:
        • Investigatore principale:
          • Lindsey A. McAlarnen
      • Omaha, Nebraska, Stati Uniti, 68198
        • Reclutamento
        • University of Nebraska Medical Center
        • Contatto:
        • Investigatore principale:
          • Lindsey A. McAlarnen
      • Omaha, Nebraska, Stati Uniti, 68114
        • Reclutamento
        • Nebraska Methodist Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 402-354-5144
        • Investigatore principale:
          • Brent J. Tierney
      • Omaha, Nebraska, Stati Uniti, 68118
        • Reclutamento
        • Nebraska Medicine-Village Pointe
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 402-559-5600
        • Investigatore principale:
          • Lindsey A. McAlarnen
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89106
        • Reclutamento
        • Women's Cancer Center of Nevada
        • Investigatore principale:
          • Nicola M. Spirtos
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 702-851-4672
    • New Jersey
      • Basking Ridge, New Jersey, Stati Uniti, 07920
        • Reclutamento
        • Memorial Sloan Kettering Basking Ridge
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Carol Aghajanian
      • Camden, New Jersey, Stati Uniti, 08103
        • Reclutamento
        • Cooper Hospital University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 856-325-6757
        • Investigatore principale:
          • Courtney Griffiths
      • Hamilton, New Jersey, Stati Uniti, 08690
        • Reclutamento
        • The Cancer Institute of New Jersey Hamilton
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 609-631-6946
        • Investigatore principale:
          • Eugenia Girda
      • Jersey City, New Jersey, Stati Uniti, 07302
        • Reclutamento
        • Jersey City Medical Center
        • Contatto:
        • Investigatore principale:
          • Eugenia Girda
      • Livingston, New Jersey, Stati Uniti, 07039
        • Reclutamento
        • Cooperman Barnabas Medical Center
        • Investigatore principale:
          • Eugenia Girda
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 973-322-5200
      • Middletown, New Jersey, Stati Uniti, 07748
        • Reclutamento
        • Memorial Sloan Kettering Monmouth
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Carol Aghajanian
      • Montvale, New Jersey, Stati Uniti, 07645
        • Reclutamento
        • Memorial Sloan Kettering Bergen
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Carol Aghajanian
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Reclutamento
        • Rutgers Cancer Institute of New Jersey
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 732-235-7356
        • Investigatore principale:
          • Eugenia Girda
      • Newark, New Jersey, Stati Uniti, 07101
        • Reclutamento
        • Rutgers New Jersey Medical School
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 732-235-7356
        • Investigatore principale:
          • Eugenia Girda
      • Paramus, New Jersey, Stati Uniti, 07652
        • Reclutamento
        • The Valley Hospital - Luckow Pavilion
        • Investigatore principale:
          • Eleonora Teplinsky
        • Contatto:
      • Ridgewood, New Jersey, Stati Uniti, 07450
        • Reclutamento
        • Valley Health System Ridgewood Campus
        • Investigatore principale:
          • Eleonora Teplinsky
        • Contatto:
      • Sewell, New Jersey, Stati Uniti, 08080
        • Reclutamento
        • Sidney Kimmel Cancer Center Washington Township
        • Contatto:
        • Investigatore principale:
          • Jessa Suhner
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • Reclutamento
        • University of New Mexico Cancer Center
        • Contatto:
        • Investigatore principale:
          • Amaranta D. Craig
    • New York
      • Bay Shore, New York, Stati Uniti, 11706
        • Reclutamento
        • Northwell Health Imbert Cancer Center
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 516-734-8896
      • Commack, New York, Stati Uniti, 11725
        • Reclutamento
        • Memorial Sloan Kettering Commack
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Carol Aghajanian
      • Flushing, New York, Stati Uniti, 11354
        • Reclutamento
        • Northwell Health Physician Partners at Flushing
        • Investigatore principale:
          • Veena S. John
        • Contatto:
      • Greenlawn, New York, Stati Uniti, 11740
        • Reclutamento
        • Northwell Health Cancer Institute at Huntington
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 516-734-8896
      • Harrison, New York, Stati Uniti, 10604
        • Reclutamento
        • Memorial Sloan Kettering Westchester
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Carol Aghajanian
      • Lake Success, New York, Stati Uniti, 11042
        • Reclutamento
        • Northwell Health/Center for Advanced Medicine
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 516-734-8896
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Carol Aghajanian
      • New York, New York, Stati Uniti, 10011
        • Reclutamento
        • Mount Sinai Chelsea
        • Investigatore principale:
          • Stephanie V. Blank
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-824-7309
          • Email: CCTO@mssm.edu
      • New York, New York, Stati Uniti, 10029
        • Reclutamento
        • Mount Sinai Hospital
        • Investigatore principale:
          • Stephanie V. Blank
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-824-7309
          • Email: CCTO@mssm.edu
      • New York, New York, Stati Uniti, 10075
        • Reclutamento
        • Lenox Hill Hospital
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 516-734-8896
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Manhattan Eye Ear and Throat Hospital
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-434-4460
      • New York, New York, Stati Uniti, 10019
        • Reclutamento
        • Mount Sinai West
        • Investigatore principale:
          • Stephanie V. Blank
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-824-7309
          • Email: CCTO@mssm.edu
      • Rego Park, New York, Stati Uniti, 11374
        • Reclutamento
        • Queens Cancer Center
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 718-312-3446
      • Rochester, New York, Stati Uniti, 14642
        • Reclutamento
        • University of Rochester
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 585-275-5830
        • Investigatore principale:
          • Rachael Turner
      • Sleepy Hollow, New York, Stati Uniti, 10591
        • Reclutamento
        • Phelps Memorial Hospital Center
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 914-366-1600
      • Staten Island, New York, Stati Uniti, 10305
        • Reclutamento
        • Staten Island University Hospital
        • Investigatore principale:
          • Veena S. John
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 718-226-8888
      • Stony Brook, New York, Stati Uniti, 11794
        • Reclutamento
        • Stony Brook University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-862-2215
        • Investigatore principale:
          • Susan M. Lang
      • Syracuse, New York, Stati Uniti, 13210
        • Reclutamento
        • State University of New York Upstate Medical University
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 315-464-5476
        • Investigatore principale:
          • Mary J. Cunningham
      • The Bronx, New York, Stati Uniti, 10461
        • Reclutamento
        • Montefiore Medical Center-Einstein Campus
        • Contatto:
        • Investigatore principale:
          • Nicole S. Nevadunsky
      • The Bronx, New York, Stati Uniti, 10467
        • Reclutamento
        • Montefiore Medical Center - Moses Campus
        • Contatto:
        • Investigatore principale:
          • Nicole S. Nevadunsky
      • The Bronx, New York, Stati Uniti, 10461
        • Reclutamento
        • Montefiore Medical Center-Weiler Hospital
        • Contatto:
        • Investigatore principale:
          • Nicole S. Nevadunsky
      • Uniondale, New York, Stati Uniti, 11553
        • Reclutamento
        • Memorial Sloan Kettering Nassau
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Carol Aghajanian
      • Webster, New York, Stati Uniti, 14580
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • Reclutamento
        • UNC Lineberger Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Olivia D. Lara
      • Clinton, North Carolina, Stati Uniti, 28328
        • Reclutamento
        • Southeastern Medical Oncology Center-Clinton
        • Contatto:
        • Investigatore principale:
          • Samer S. Kasbari
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 888-275-3853
        • Investigatore principale:
          • Jennifer L. McNally
      • Goldsboro, North Carolina, Stati Uniti, 27534
        • Reclutamento
        • Southeastern Medical Oncology Center-Goldsboro
        • Contatto:
        • Investigatore principale:
          • Samer S. Kasbari
      • Jacksonville, North Carolina, Stati Uniti, 28546
        • Reclutamento
        • Southeastern Medical Oncology Center-Jacksonville
        • Investigatore principale:
          • Samer S. Kasbari
        • Contatto:
      • Raleigh, North Carolina, Stati Uniti, 27607
        • Reclutamento
        • Duke Women's Cancer Care Raleigh
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 919-785-4878
        • Investigatore principale:
          • Jennifer L. McNally
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58103
        • Reclutamento
        • Essentia Health Cancer Center-South University Clinic
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
    • Ohio
      • Athens, Ohio, Stati Uniti, 45701
        • Reclutamento
        • OhioHealth O'Bleness Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Beachwood, Ohio, Stati Uniti, 44122
        • Reclutamento
        • UHHS-Chagrin Highlands Medical Center
        • Contatto:
        • Investigatore principale:
          • Amy Armstrong
      • Canton, Ohio, Stati Uniti, 44710
        • Reclutamento
        • Aultman Health Foundation
        • Contatto:
        • Investigatore principale:
          • Sunitha Vemulapalli
      • Chardon, Ohio, Stati Uniti, 44024
        • Reclutamento
        • Geauga Hospital
        • Contatto:
        • Investigatore principale:
          • Amy Armstrong
      • Cleveland, Ohio, Stati Uniti, 44106
        • Reclutamento
        • Case Western Reserve University
        • Contatto:
        • Investigatore principale:
          • Amy Armstrong
      • Columbus, Ohio, Stati Uniti, 43214
        • Reclutamento
        • Columbus Oncology and Hematology Associates Inc
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43214
        • Reclutamento
        • Riverside Methodist Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43215
        • Reclutamento
        • Grant Medical Center
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43228
        • Reclutamento
        • Doctors Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43210
        • Reclutamento
        • Ohio State University Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Floor Backes
      • Delaware, Ohio, Stati Uniti, 43015
        • Reclutamento
        • Delaware Health Center-Grady Cancer Center
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Delaware, Ohio, Stati Uniti, 43015
        • Reclutamento
        • Grady Memorial Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Dublin, Ohio, Stati Uniti, 43016
        • Reclutamento
        • Columbus Oncology and Hematology Associates
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Dublin, Ohio, Stati Uniti, 43016
        • Reclutamento
        • Dublin Methodist Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Mansfield, Ohio, Stati Uniti, 44903
        • Reclutamento
        • OhioHealth Mansfield Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Marion, Ohio, Stati Uniti, 43302
        • Reclutamento
        • OhioHealth Marion General Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Mentor, Ohio, Stati Uniti, 44060
        • Reclutamento
        • UH Seidman Cancer Center at Lake Health Mentor Campus
        • Contatto:
        • Investigatore principale:
          • Amy Armstrong
      • Parma, Ohio, Stati Uniti, 44129
        • Reclutamento
        • University Hospitals Parma Medical Center
        • Contatto:
        • Investigatore principale:
          • Amy Armstrong
      • Pickerington, Ohio, Stati Uniti, 43147
        • Reclutamento
        • OhioHealth Pickerington Methodist Hospital
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Sylvania, Ohio, Stati Uniti, 43560
        • Reclutamento
        • ProMedica Flower Hospital
        • Contatto:
        • Investigatore principale:
          • Anjalika Gandhi
      • Westerville, Ohio, Stati Uniti, 43082
        • Reclutamento
        • OhioHealth Westerville Medical Campus/Westerville Cancer Center
        • Investigatore principale:
          • Aine E. Clements
        • Contatto:
      • Westlake, Ohio, Stati Uniti, 44145
        • Reclutamento
        • UH Seidman Cancer Center at Saint John Medical Center
        • Contatto:
        • Investigatore principale:
          • Amy Armstrong
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Reclutamento
        • University of Oklahoma Health Sciences Center
        • Contatto:
        • Investigatore principale:
          • Grace Duininck
    • Oregon
      • Portland, Oregon, Stati Uniti, 97213
        • Reclutamento
        • Providence Portland Medical Center
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Portland, Oregon, Stati Uniti, 97225
        • Reclutamento
        • Providence Saint Vincent Medical Center
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Portland, Oregon, Stati Uniti, 97210
        • Reclutamento
        • Legacy Good Samaritan Hospital and Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-220-4937
          • Email: cancer@lhs.org
        • Investigatore principale:
          • Julia Fehniger
      • Tualatin, Oregon, Stati Uniti, 97062
        • Reclutamento
        • Legacy Meridian Park Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 503-413-1742
        • Investigatore principale:
          • Julia Fehniger
    • Pennsylvania
      • Erie, Pennsylvania, Stati Uniti, 16505
        • Reclutamento
        • UPMC Hillman Cancer Center Erie
        • Investigatore principale:
          • Sarah E. Taylor
        • Contatto:
      • Greensburg, Pennsylvania, Stati Uniti, 15601
        • Reclutamento
        • UPMC Cancer Centers - Arnold Palmer Pavilion
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 724-838-1900
        • Investigatore principale:
          • Sarah E. Taylor
      • Hershey, Pennsylvania, Stati Uniti, 17033-0850
        • Reclutamento
        • Penn State Milton S Hershey Medical Center
        • Investigatore principale:
          • Mark S. Shahin
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 717-531-3779
          • Email: CTO@hmc.psu.edu
      • Mechanicsburg, Pennsylvania, Stati Uniti, 17050
        • Reclutamento
        • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
        • Contatto:
        • Investigatore principale:
          • Sarah E. Taylor
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Reclutamento
        • Thomas Jefferson University Hospital
        • Contatto:
        • Investigatore principale:
          • Jessa Suhner
      • Philadelphia, Pennsylvania, Stati Uniti, 19114
        • Reclutamento
        • Jefferson Torresdale Hospital
        • Contatto:
        • Investigatore principale:
          • Jessa Suhner
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • Reclutamento
        • UPMC-Magee Womens Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-647-2811
        • Investigatore principale:
          • Sarah E. Taylor
      • Pittsburgh, Pennsylvania, Stati Uniti, 15237
        • Reclutamento
        • UPMC-Passavant Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-367-6454
        • Investigatore principale:
          • Sarah E. Taylor
      • Washington, Pennsylvania, Stati Uniti, 15301
        • Reclutamento
        • UPMC Cancer Center-Washington
        • Contatto:
        • Investigatore principale:
          • Sarah E. Taylor
      • Willow Grove, Pennsylvania, Stati Uniti, 19090
        • Reclutamento
        • Asplundh Cancer Pavilion
        • Contatto:
        • Investigatore principale:
          • Jessa Suhner
    • Rhode Island
      • Providence, Rhode Island, Stati Uniti, 02903
        • Reclutamento
        • Rhode Island Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 401-444-1488
        • Investigatore principale:
          • Boris Martinez
      • Providence, Rhode Island, Stati Uniti, 02905
        • Reclutamento
        • Women and Infants Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 401-274-1122
        • Investigatore principale:
          • Paul A. DiSilvestro
    • Tennessee
      • Franklin, Tennessee, Stati Uniti, 37067
        • Reclutamento
        • Vanderbilt-Ingram Cancer Center Cool Springs
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-811-8480
        • Investigatore principale:
          • Alaina J. Brown
      • Nashville, Tennessee, Stati Uniti, 37232
        • Reclutamento
        • Vanderbilt University/Ingram Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-811-8480
        • Investigatore principale:
          • Alaina J. Brown
      • Nashville, Tennessee, Stati Uniti, 37204
        • Reclutamento
        • Vanderbilt Breast Center at One Hundred Oaks
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-811-8480
        • Investigatore principale:
          • Alaina J. Brown
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84106
        • Reclutamento
        • University of Utah Sugarhouse Health Center
        • Contatto:
        • Investigatore principale:
          • Talicia Savage
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Reclutamento
        • Huntsman Cancer Institute/University of Utah
        • Contatto:
        • Investigatore principale:
          • Talicia Savage
      • South Jordan, Utah, Stati Uniti, 84009
        • Reclutamento
        • South Jordan Health Center
        • Contatto:
        • Investigatore principale:
          • Talicia Savage
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Reclutamento
        • University of Virginia Cancer Center
        • Contatto:
        • Investigatore principale:
          • Matthew K. Wagar
      • Richmond, Virginia, Stati Uniti, 23298
        • Reclutamento
        • VCU Massey Comprehensive Cancer Center
        • Investigatore principale:
          • Jaclyn Wall
        • Contatto:
    • Washington
      • Edmonds, Washington, Stati Uniti, 98026
        • Reclutamento
        • Swedish Cancer Institute-Edmonds
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Issaquah, Washington, Stati Uniti, 98029
        • Reclutamento
        • Swedish Cancer Institute-Issaquah
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Seattle, Washington, Stati Uniti, 98122
        • Reclutamento
        • Swedish Medical Center-First Hill
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Seattle, Washington, Stati Uniti, 98195
        • Reclutamento
        • University of Washington Medical Center - Montlake
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-804-8824
        • Investigatore principale:
          • Heidi J. Gray
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • Fred Hutchinson Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-804-8824
        • Investigatore principale:
          • Heidi J. Gray
      • Vancouver, Washington, Stati Uniti, 98686
        • Reclutamento
        • Legacy Salmon Creek Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 503-413-2150
        • Investigatore principale:
          • Julia Fehniger
    • West Virginia
      • Bridgeport, West Virginia, Stati Uniti, 26330
        • Reclutamento
        • United Hospital Center
        • Contatto:
        • Investigatore principale:
          • Krista S. Pfaendler
      • Charleston, West Virginia, Stati Uniti, 25304
        • Reclutamento
        • Vandalia Health/CAMC Institute for Academic Medicine
        • Investigatore principale:
          • Stephen H. Bush
        • Contatto:
      • Martinsburg, West Virginia, Stati Uniti, 25401
        • Reclutamento
        • WVUH-Berkely Medical Center
        • Contatto:
        • Investigatore principale:
          • Krista S. Pfaendler
      • Morgantown, West Virginia, Stati Uniti, 26506
        • Reclutamento
        • West Virginia University Healthcare
        • Contatto:
        • Investigatore principale:
          • Krista S. Pfaendler
      • Parkersburg, West Virginia, Stati Uniti, 26101
        • Reclutamento
        • Camden Clark Medical Center
        • Contatto:
        • Investigatore principale:
          • Krista S. Pfaendler
    • Wisconsin
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Reclutamento
        • Duluth Clinic Ashland
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Green Bay, Wisconsin, Stati Uniti, 54301
        • Reclutamento
        • Saint Vincent Hospital Cancer Center Green Bay
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • Green Bay, Wisconsin, Stati Uniti, 54303
        • Reclutamento
        • Saint Vincent Hospital Cancer Center at Saint Mary's
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • La Crosse, Wisconsin, Stati Uniti, 54601
        • Reclutamento
        • Gundersen Lutheran Medical Center
        • Contatto:
        • Investigatore principale:
          • Gil Harmon
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Medical College of Wisconsin
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 414-805-3666
        • Investigatore principale:
          • William H. Bradley
      • Oconto Falls, Wisconsin, Stati Uniti, 54154
        • Reclutamento
        • Saint Vincent Hospital Cancer Center at Oconto Falls
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • Sheboygan, Wisconsin, Stati Uniti, 53081
        • Reclutamento
        • Saint Vincent Hospital Cancer Center at Sheboygan
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • Sheboygan, Wisconsin, Stati Uniti, 53081
        • Reclutamento
        • Sheboygan Physicians Group
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • Spooner, Wisconsin, Stati Uniti, 54801
        • Reclutamento
        • Essentia Health-Spooner Clinic
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Sturgeon Bay, Wisconsin, Stati Uniti, 54235-1495
        • Reclutamento
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
        • Investigatore principale:
          • Matthew L. Ryan
        • Contatto:
      • Superior, Wisconsin, Stati Uniti, 54880
        • Reclutamento
        • Essentia Health Saint Mary's Hospital - Superior
        • Investigatore principale:
          • Bret E. Friday
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 701-364-6272

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Documentation of disease:

    • Stage III and stage IVA endometrial cancers (with measurable disease),
    • Stage IVB endometrial cancer (with or without measurable disease), or
    • Recurrent endometrial cancer (with or without measurable disease)
  • In patients with measurable disease, lesions will be defined and monitored by RECIST 1.1. Measurable disease (RECIST 1.1) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT or MRI. Lymph nodes must be ≥ 15 mm in short axis when measured by CT or MRI

  • Histologic confirmation of the original primary tumor is required (submission of pathology report[s] is required). Patients with the following histologic types are eligible: endometrioid, serous, dedifferentiated/undifferentiated, clear cell, mixed epithelial, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.)

  • Patients must have:

    • Tumoral mismatch repair proficient (pMMR) disease as assessed by immunohistochemistry (IHC) AND
    • P53 IHC with aberrant staining pattern (aberrant p53 expression is consistent with mutant TP53). TP53 mutation by next-generation sequencing will also be accepted
  • A pathology report demonstrating results of institutional MMR IHC and p53 IHC and/or TP53 by next-generation sequencing

  • Patients may have received:

    • NO prior chemotherapy for treatment of endometrial cancer OR
    • Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed ≥ 12 months prior to registration
  • Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration. For patients with recent radiation, they must have RECIST-evaluable disease outside of the radiation field and have recovered their marrow function

  • Patients may have received prior hormonal (endocrine) therapy. All hormonal (endocrine) therapy must have been completed at least 1 week prior to registration

  • NO prior pembrolizumab (or other anti-PD1, anti-PDL1 or anti-CTLA4 therapy) or bevacizumab (or other antiangiogenic therapy)

  • Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of disease progression. Patients with brain metastases must have follow up imaging demonstrating no evidence of disease progression and that the disease is stable off of steroids

  • Age ≥ 18

  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

  • Not pregnant and not nursing

  • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3

  • Platelets ≥ 100,000 cells/mm^3

  • Hemoglobin ≥ 8 g/dl

  • Creatinine clearance (CrCl) of ≥ 30 mL/min by the Cockcroft-Gault formula

  • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better

  • No active infection requiring parenteral antibiotics

  • No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube

  • No clinically significant bleeding within 28 days prior to registration

  • No uncontrolled hypertension, defined as systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg

  • No major surgery within 28 days of initiation of bevacizumab

  • No active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease

    • Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
    • Topical or inhaled steroids are allowed
    • Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), and anti-thyroid antibodies should be evaluated with the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
  • No history of (non-infectious) pneumonitis that required steroids, or current pneumonitis

  • No history of stem cell or solid organ transplant

  • No history of allergic reaction to the study agent(s) or compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Arm 1 (paclitaxel, carboplatin, pembrolizumab)

Patients receive paclitaxel IV over 3 hours, carboplatin IV and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to an additional 14 cycles. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Given IV

Altri nomi:
  • Tassolo
  • Anzatax
  • Asotax
  • Bristaxolo
  • Praxel
  • Taxol Konzentrat

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Given IV

Altri nomi:
  • Chiavetruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475
  • MK3475
  • SCH-900475
  • BCD-201
  • Pembrolizumab biosimilare BCD-201
  • Pembrolizumab biosimilare QL2107
  • QL2107
  • GME751
  • Pembrolizumab biosimilare GME751
  • SCH900475
  • Pembrolizumab biosimilare RPH-075
  • RPH 075
  • RPH-075
  • RPH075
  • Pembrolizumab Biosimilar SB27
  • SB 27
  • SB-27
  • SB27

Undergo urine and blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione
Sperimentale: Arm 2 (paclitaxel, carboplatin, bevacizumab)

Patients receive paclitaxel IV over 3 hours, carboplatin IV, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Given IV

Altri nomi:
  • Tassolo
  • Anzatax
  • Asotax
  • Bristaxolo
  • Praxel
  • Taxol Konzentrat

Given IV

Altri nomi:
  • Avastin
  • SOA 215
  • Anti-VEGF
  • Anticorpo monoclonale umanizzato anti-VEGF
  • Anticorpo monoclonale anti-VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab biosimilare ABP 215
  • Bevacizumab biosimilare BEVZ92
  • Bevacizumab biosimilare BI 695502
  • Bevacizumab biosimilare CBT 124
  • Bevacizumab biosimilare CT-P16
  • Bevacizumab biosimilare FKB238
  • Bevacizumab biosimilare GB-222
  • Bevacizumab biosimilare HD204
  • Bevacizumab biosimilare HLX04
  • Bevacizumab biosimilare IBI305
  • Bevacizumab biosimilare LY01008
  • Bevacizumab biosimilare MIL60
  • Bevacizumab biosimilare Mvasi
  • Bevacizumab biosimilare MYL-1402O
  • Bevacizumab biosimilare QL 1101
  • Bevacizumab biosimilare RPH-001
  • Bevacizumab biosimilare SCT501
  • Bevacizumab Biosimilare Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilare
  • HD204
  • Immunoglobulina G1 (fattore di crescita endoteliale vascolare monoclonale umano-topo rhuMab-VEGF anti-catena gamma), disolfuro con catena leggera monoclonale umano-topo rhuMab-VEGF, dimero
  • Mvasi
  • MYL-1402O
  • Anticorpo monoclonale anti-VEGF umanizzato ricombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab biosimilare QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilare
  • Bevacizumab biosimilare BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-mal
  • Bevacizumab-onbe
  • CT P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab biosimilare MB02
  • Bevacizumab-tnjn
  • FKB238
  • FKB-238
  • MB02
  • MB-02
  • Oyavas
  • PF06439535
  • PF-06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo urine and blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione
Sperimentale: Arm 3 (paclitaxel, carboplatin, pembrolizumab, bevacizumab)

Patients receive paclitaxel IV over 3 hours, carboplatin IV, pembrolizumab IV over 30 minutes, and bevacizumab IV or anti-VEGF antibody biosimilar on day 1 of each cycle. Cycles repeat every 3 weeks for up to 6-10 cycles in the absence of disease progression or unacceptable toxicity. Starting 3 weeks after last combination phase cycle, patients may continue to receive maintenance pembrolizumab IV over 30 minutes every 6 weeks for up to an additional 14 cycles and bevacizumab IV every 3 weeks for up to an additional 28 doses. Additionally, patients undergo urine and blood sample collection and CT or MRI throughout the study.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Given IV

Altri nomi:
  • Tassolo
  • Anzatax
  • Asotax
  • Bristaxolo
  • Praxel
  • Taxol Konzentrat

Given IV

Altri nomi:
  • Avastin
  • SOA 215
  • Anti-VEGF
  • Anticorpo monoclonale umanizzato anti-VEGF
  • Anticorpo monoclonale anti-VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab biosimilare ABP 215
  • Bevacizumab biosimilare BEVZ92
  • Bevacizumab biosimilare BI 695502
  • Bevacizumab biosimilare CBT 124
  • Bevacizumab biosimilare CT-P16
  • Bevacizumab biosimilare FKB238
  • Bevacizumab biosimilare GB-222
  • Bevacizumab biosimilare HD204
  • Bevacizumab biosimilare HLX04
  • Bevacizumab biosimilare IBI305
  • Bevacizumab biosimilare LY01008
  • Bevacizumab biosimilare MIL60
  • Bevacizumab biosimilare Mvasi
  • Bevacizumab biosimilare MYL-1402O
  • Bevacizumab biosimilare QL 1101
  • Bevacizumab biosimilare RPH-001
  • Bevacizumab biosimilare SCT501
  • Bevacizumab Biosimilare Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilare
  • HD204
  • Immunoglobulina G1 (fattore di crescita endoteliale vascolare monoclonale umano-topo rhuMab-VEGF anti-catena gamma), disolfuro con catena leggera monoclonale umano-topo rhuMab-VEGF, dimero
  • Mvasi
  • MYL-1402O
  • Anticorpo monoclonale anti-VEGF umanizzato ricombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab biosimilare QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilare
  • Bevacizumab biosimilare BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-mal
  • Bevacizumab-onbe
  • CT P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab biosimilare MB02
  • Bevacizumab-tnjn
  • FKB238
  • FKB-238
  • MB02
  • MB-02
  • Oyavas
  • PF06439535
  • PF-06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Given IV

Altri nomi:
  • Chiavetruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475
  • MK3475
  • SCH-900475
  • BCD-201
  • Pembrolizumab biosimilare BCD-201
  • Pembrolizumab biosimilare QL2107
  • QL2107
  • GME751
  • Pembrolizumab biosimilare GME751
  • SCH900475
  • Pembrolizumab biosimilare RPH-075
  • RPH 075
  • RPH-075
  • RPH075
  • Pembrolizumab Biosimilar SB27
  • SB 27
  • SB-27
  • SB27

Undergo urine and blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS)
Lasso di tempo: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Will be defined using Response Evaluation Criteria in Solid Tumors version (v) 1.1. Will be tested using one-sided log-rank tests with α-levels stratified by factors used in the randomization. Patients will be grouped by their randomized treatment assignment for intention-to-treat (ITT) analyses, supported by patients in ITT population. Treatment hazard ratios and their 95% confidence intervals will be estimated using a Cox proportional hazards models specified with a main effect for the randomized treatment assignment and stratified using the stratification factors applied at randomization.

From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall survival (OS)
Lasso di tempo: From study entry to time of death from any cause, assessed up to 5 years

Will be assessed with proportional hazards modeling stratified for stratification factors at baseline. Hazard ratios and corresponding 2-sided 95% confidence intervals will be estimated for treatment (with Arm 1 as the reference arm).

From study entry to time of death from any cause, assessed up to 5 years
Prognostic and predictive associations of type of TP53 mutation status with PFS
Lasso di tempo: Up to 5 years

Will be assessed with proportional hazards modeling stratified for stratification factors at baseline and adjusted by randomized treatment arm assignment. Hazard ratios and corresponding 2-sided 95% confidence intervals will be estimated for TP53 status as well as treatment hazard ratios (with Arm 1 as the reference arm) within TP53 subgroups.

Up to 5 years
Prognostic and predictive associations of type of TP53 mutation status with OS
Lasso di tempo: Up to 5 years

Will be assessed with proportional hazards modeling stratified for stratification factors at baseline and adjusted by randomized treatment arm assignment. Hazard ratios and corresponding 2-sided 95% confidence intervals will be estimated for TP53 status as well as treatment hazard ratios (with Arm 1 as the reference arm) within TP53 subgroups.

Up to 5 years
Incidence of adverse events (AEs) in treatment with bevacizumab when combined with carboplatin, paclitaxel, and pembrolizumab
Lasso di tempo: Up to 90 days after last dose of study treatment

The nature, frequency, and degree of toxicity will be tabulated at the system organ class and AE-specific term levels using Common Terminology Criteria for Adverse Events v 5.0. Each patient will be represented according to maximum grade observed for each term. Tabulations will show the number and percentage of patients by maximum grade, within the treatment group received, regardless of the randomized treatment assignment. No specific hypothesis test is pre-specified.

Up to 90 days after last dose of study treatment
Objective response rate
Lasso di tempo: Within 12 months of initiating therapy

Will be defined as the binomial proportion of evaluable patients with a best overall response of complete response or partial response. Will be supported by their 2-sided, 95% Wilson-Score confidence intervals. The relative odds of response in each experimental group (vs the reference group) will be estimated using a multivariable logistic regression model specified with main effects for the treatment groups and stratified by the stratification factors reported at baseline.

Within 12 months of initiating therapy

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
PFS
Lasso di tempo: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Will estimate the PFS treatment effect and the corresponding 95% confidence intervals by sex.

From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years
PFS
Lasso di tempo: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Will estimate the PFS treatment effect and the corresponding 95% confidence intervals by race.

From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years
PFS
Lasso di tempo: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Will estimate the PFS treatment effect and the corresponding 95% confidence intervals by ethnicity.

From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Amanda N Fader, NRG Oncology

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 gennaio 2026

Completamento primario (Stimato)

1 luglio 2028

Completamento dello studio (Stimato)

1 luglio 2028

Date di iscrizione allo studio

Primo inviato

27 settembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

27 settembre 2025

Primo Inserito (Effettivo)

30 settembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi